

Edgar Filing: IMMUNOGEN INC - Form 8-K

IMMUNOGEN INC  
Form 8-K  
October 15, 2002

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934  
-----

Date of Report (Date of earliest event reported): October 8, 2002

IMMUNOGEN, INC.  
(Exact name of registrant as specified in its Charter)

Massachusetts	0-17999	04-2726691
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

128 Sidney Street, Cambridge, Massachusetts 02139  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (617) 995-2500

ITEM 5. OTHER EVENTS

On October 8, 2002, Boehringer Ingelheim GmbH informed ImmunoGen, Inc. that clinical trials of the novel anti-cancer agent composed of ImmunoGen's DM1 Tumor-Activated Prodrug (TAP technology) and Boehringer Ingelheim's anti-CD44v6 antibody had been initiated on or about September 24, 2002. The achievement of this milestone triggers a milestone payment of \$1.0 million from Boehringer Ingelheim to ImmunoGen. This milestone payment will be recognized as revenue in ImmunoGen's quarter ended September 30, 2002, the period in which the milestone payment was earned. The press release announcing the achievement of this milestone is incorporated herein by reference and filed as Exhibit 99.1 hereto.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

99.1 The Registrant's Press Release dated October 15, 2002.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,

Edgar Filing: IMMUNOGEN INC - Form 8-K

the Registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

ImmunoGen, Inc.  
(Registrant)

Date: October 15, 2002

/s/ GREGG D. BELOFF

-----  
Gregg D. Beloff  
Chief Financial Officer  
and Vice President